Photocure ASA logo

PHO - Photocure ASA Share Price

NOK92.7 -3.6  -3.7%

Last Trade - 3:25pm

Sector
Healthcare
Size
Small Cap
Market Cap £173.4m
Enterprise Value £166.1m
Revenue £17.8m
Position in Universe 645th / 1714
Bullish
Bearish
Unlock PHO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PHO Revenue Unlock PHO Revenue

Net Income

PHO Net Income Unlock PHO Revenue

Normalised EPS

PHO Normalised EPS Unlock PHO Revenue

PE Ratio Range

PHO PE Ratio Range Unlock PHO Revenue

Dividend Yield Range

PHO Dividend Yield Range Unlock PHO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PHO EPS Forecasts Unlock PHO Revenue
Profile Summary

Photocure ASA is a Norway-based company active in the pharmaceutical industry. It operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The Company is a parent of a wholly owned entity, Photocure Inc.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated February 20, 1995
Public Since May 29, 2000
No. of Shareholders: n/a
No. of Employees: 71
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Oslo Stock Exchange
Shares in Issue 21,779,763
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PHO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PHO
Upcoming Events for PHO
Thursday 27th February, 2020
Q4 2019 Photocure ASA Earnings Call
Thursday 27th February, 2020
Q4 2019 Photocure ASA Earnings Release
Similar to PHO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.